Lyrica (pregabalin) is a Schedule V controlled substance because it produces euphoria at rates significantly higher than expected and carries a real, if relatively low, risk of abuse and dependence. Schedule V is the least restrictive category under the Controlled Substances Act, meaning the DEA determined that pregabalin has legitimate medical uses and a lower abuse potential than drugs in higher schedules, but enough risk that it can’t be treated like an ordinary prescription medication.
What the DEA Found Before Scheduling
When the DEA evaluated pregabalin in 2005, it applied a three-part test required by federal law. The agency concluded that pregabalin has a low potential for abuse compared to Schedule IV drugs like benzodiazepines, that it has accepted medical uses in the U.S., and that misuse may lead to limited physical or psychological dependence.
The clinical trial data played a major role in that decision. In studies of patients with generalized anxiety disorder, 11.8% of people taking the 450 mg dose reported euphoria, compared to just 1.2% on placebo. At the 200 mg dose, that figure was 10.3%. The FDA’s pharmacology review noted that this rate of euphoria was “unusually high.” Pregabalin also produced effects similar to those of diazepam and alprazolam (both Schedule IV benzodiazepines), and animal studies showed the drug was self-administered at rates above baseline, though well below classic drugs of abuse like barbiturates.
Beyond euphoria, trial participants on pregabalin experienced dizziness, drowsiness, blurred vision, weight gain, and difficulty concentrating more often than those on placebo. Taken together, these psychoactive effects convinced regulators that pregabalin needed to be controlled, even if it didn’t rise to the level of more tightly restricted drugs.
How Pregabalin Affects the Brain
Despite having “GABA” in its chemical family name (it belongs to a class called gabapentinoids), pregabalin does not actually bind to GABA receptors, get converted into GABA, or interact with GABA transport systems. Its real target is a specific subunit on voltage-gated calcium channels in nerve cells. By binding to that subunit, pregabalin reduces the release of several excitatory chemical messengers in the brain, which is why it calms overactive nerve signaling in conditions like epilepsy, nerve pain, and anxiety.
That calming effect is also the source of its abuse potential. At high doses, the dampening of nerve activity can produce feelings of relaxation, sedation, dissociation, and euphoria. Some users describe improved sociability and a sense of emotional warmth. These pleasurable effects are what make the drug appealing beyond its prescribed purpose.
How Pregabalin Gets Misused
Most misuse involves taking doses far higher than prescribed. Therapeutic doses typically range from 150 to 600 mg per day, but case reports document people consuming up to 7,500 mg daily, or 3 to 20 times the recommended amount, to chase euphoria or heightened energy. While most users take it orally, some have injected, smoked, or inhaled it.
Pregabalin misuse is especially common among people already using other substances. In methadone treatment programs, some patients take high doses to boost the effects of methadone, reduce withdrawal symptoms from other drugs, or simply get high. It’s frequently combined with alcohol, benzodiazepines, opioids, cannabis, and sleep medications to amplify the overall effect. That combination strategy is particularly dangerous: using pregabalin alongside opioids or other sedating drugs significantly raises the risk of fatal respiratory depression, where breathing slows to a life-threatening degree.
In 2019, the FDA issued a safety warning specifically about this risk, requiring new label warnings about serious breathing problems when pregabalin is used alongside opioids or in people with reduced lung function from conditions like COPD. The agency also ordered drug manufacturers to conduct additional clinical trials evaluating abuse potential when pregabalin is combined with opioids, citing rising rates of co-use.
Withdrawal and Physical Dependence
One of the criteria for controlled substance scheduling is whether a drug causes physical dependence, and pregabalin does. When someone who has been taking it regularly, especially at high doses, stops abruptly, the brain essentially rebounds. During long-term use, the nervous system adapts to pregabalin’s calming influence by becoming more excitable at baseline. Remove the drug, and that suppressed activity surges back.
Withdrawal symptoms typically emerge within 24 to 48 hours of the last dose and can include rapid heartbeat, tremors, irritability, insomnia, anxiety, sweating, and fatigue. In severe cases involving very high doses, people have experienced auditory hallucinations, paranoia, and suicidal thoughts. One documented case involved a man taking 8,400 mg daily who developed sweating, racing heart, hallucinations, and suicidal ideation within 36 hours of stopping.
These withdrawal effects mirror what happens with other drugs that suppress brain activity. The excitatory chemical messenger glutamate floods back, the brain’s inhibitory systems are temporarily weakened, and the reward-related signaling system can overshoot, contributing to the more dramatic psychiatric symptoms. This is why tapering off pregabalin gradually, rather than stopping cold, is standard practice.
Why Schedule V and Not Higher
Schedule V is reserved for drugs with the lowest abuse potential among controlled substances. For context, Schedule IV includes benzodiazepines like Xanax and sleep medications like Ambien. Schedule III includes testosterone and ketamine. The DEA placed pregabalin in Schedule V because, while the euphoria signal in clinical trials was notable, the overall pattern of abuse in preclinical and clinical data was milder than Schedule IV comparators. Animal studies showed pregabalin was self-administered only sporadically and at much lower rates than barbiturates or benzodiazepines.
In practical terms, Schedule V status means your pharmacist keeps records of pregabalin dispensing, prescriptions have some restrictions on refills, and the drug can’t legally be shared or sold. But you won’t face the same level of prescription monitoring as you would with, say, an opioid or a stimulant. The scheduling reflects a balance: the drug is genuinely useful for nerve pain, seizures, and certain anxiety disorders, but it carries enough risk that unrestricted access would be a public health concern.